Cresco Labs Posts $173 Million Q3 Revenue
The cannabis company reported third quarter 2026 results and shareholders approved three resolutions to simplify its corporate structure.
Updated on Nov. 6, 2026 in Corporate Finance
Cresco Labs reported $173 million in revenue for the third quarter of 2026, ended September 30, with a net loss of $15 million. Shareholders separately approved three special resolutions aimed at simplifying the company's corporate structure.
Why it matters
The company says the shareholder resolutions are intended to simplify its corporate structure and align it with the U.S. investor base. The results show a business with adjusted EBITDA of $35 million and positive free cash flow, alongside a sizable $454 million in long-term notes and loans.
Cresco Labs reported $173 million in third quarter revenue, $35 million in adjusted EBITDA, and $21 million in free cash flow, with $76 million in cash and $454 million in long-term notes and loans as of September 30, 2026. The figures are unaudited and do not yet include the full financial statement filings expected November 6.
The players
Cresco Labs
A vertically integrated cannabis company that operates in multiple U.S. markets and is working toward listing on a major U.S. exchange.
The details
Cresco Labs said its third quarter SG&A totaled $58 million, or 33.4% of revenue, with the gap between reported and adjusted SG&A attributed to one-time costs tied to M&A, uplisting preparedness, and federal reform. Shareholders approved the three special resolutions with over 94% support.
Timeline
September 30, 2026: Third quarter ended and balance sheet figures were reported as of this date.
Last week, relative to November 6, 2026: Shareholders approved the three special resolutions with over 94% support.
November 6, 2026: Earnings webcast held at 8:30 a.m. Eastern Time; unaudited statements expected to be filed on SEDAR+ and EDGAR.
Market Dynamics
The restructuring fits a broader push by U.S.-focused cannabis operators to prepare for uplisting and potential federal reform. The company's preparation for these shifts is reflected in the one-time costs it reported this quarter.
Investors tracking Cresco Labs will be able to review the full unaudited financial statements once they are filed around November 6, 2026. The results show positive operating and free cash flow, but readers should weigh the company's $454 million in long-term debt against those cash generation figures.
The takeaway
Readers following cannabis companies should note that positive operating and free cash flow can coexist with a net loss and significant long-term debt. Watching whether the filed statements confirm these preliminary figures will show how the restructuring is affecting results.
What happens next
Cresco Labs expects to file its unaudited condensed interim consolidated financial statements for the quarter ended September 30, 2026, on SEDAR+ and EDGAR on or about November 6, 2026.
Further reading
For more on corporate restructuring and capital decisions, explore Corporate Finance coverage.
More information
Investor information and company updates are available on the Cresco Labs company website.
Source note: This article includes information reported by Sudbury Star.
